Latest Content

FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data.

Experts explore the clinical promise, nursing implications, and access barriers of GLP-1s in cancer care.

FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration.

FDA approves Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta, providing a new option for oncology nurses to manage chemotherapy-induced neutropenia.

Dr. Rodney Haring discusses the 2026 AACR Cancer Disparities Report and the critical role of oncology navigators in tribal and rural health equity.

ESMO GI 2026 data show patients under 50 receive more aggressive therapy yet face poorer survival, suggesting EOCRC is a distinct biological entity.

Study finds 86.5% of gastric/GEJ patients completed surgery after neoadjuvant chemo, significantly improving survival over those who did not.

Long-term data show watch-and-wait is viable for rectal cancer, with most regrowths salvageable despite adverse baseline MRI features.

Melissa Baker discusses SOPs in transplant care, gene therapy for sickle cell, and the essential role of nurses in clinical strategy and care planning.

Oncology nurse Kerry Mann details the protocols and patient-centered strategies for bringing advanced precision medicine to local community clinics.

Pamela Plasket, RN, discusses the evolving role of oncology nurses as lung cancer patients survive longer on advanced therapies like BiTEs.

Oncology nurse navigator Diane Stanaway discusses photosensitivity, new sunscreen innovations, and debunking common myths for patients and survivors.

Maite San Miguel and a new survey highlight how specialized training and clinical autonomy are vital for optimizing multiple myeloma outcomes.